Alpha-1-Antichymotrypsin Antibody / AACT / SERPINA3 | V3227-20UG

Alpha-1-Antichymotrypsin Antibody / AACT / SERPINA3 | V3227-20UG | Gentaur US, UK & Europe Disrtribition

Family: Primary antibody

Formulation: 0.2 mg/ml in 1X PBS with 0.1 mg/ml BSA (US sourced) and 0.05% sodium azide

Format: Purified

Clone: AACT/1451

Host Animal: Mouse

Clonality: Monoclonal (mouse origin)

Species Reactivity: Human

Application: IHC-P

Buffer: N/A

Limitation: This Alpha-1-Antichymotrypsin antibody is available for research use only.

Purity: Protein G affinity

Description: Alpha 1-antichymotrypsin, or AACT, is a plasma protease inhibitor synthesized in the liver as a single glycopeptide chain. In human, the normal serum level of AACT is about one-tenth that of alpha 1-antitrypsin (AAT), with which it shares nucleic acid and protein sequence homology. Both are major acute phase reactants; their concentrations in plasma increase in response to trauma, surgery and infection. Elevated levels of AACT are widely, but not universally, reported in the cerebrospinal fluid and plasma of AD patients. Prostate-specific antigen (PSA) and its SDS-stable complex with AACT are in widespread use as markers for the diagnosis of prostate cancer. AACT deficiency may also be a possible cause of chronic liver disease. AACT antibody reacts with histiocytes and histiocytic neoplasms. It is widely used to identify histiocytes and tumors derived from them. Acinar tumors of the pancreas and salivary gland may also exhibit AACT positivity.

Immunogen: A human partial recombinant protein was used as the immunogen for this Alpha-1-Antichymotrypsin antibody.

Storage: Store the Alpha-1-Antichymotrypsin antibody at 2-8oC (with azide) or aliquot and store at -20 °C or colder (without azide).